Author: claimsbot

1. For use in a mobile station capable of accessing a wireless network, an apparatus for transferring geographic location information associated with said mobile station to a server accessible via a communication network coupled to said wireless network, said apparatus composing:
memory that comprises mobile station current position information and at least one encryptiondecryption key; and
a controller, coupled to the memory, that is capable of determining the geographic location information and storing it in the memory, the controller additionally capable of establishing a secure connection with the server, using the at least one encryptiondecryption key, over the wireless network over which the geographic location information is transmitted.
2. The apparatus as set forth in claim 1 and further including a position locator that establishes said geographic location information for said controller.
3. The apparatus as set forth in claim 2 wherein said position locator is a global positioning system receiver.
4. The apparatus as set forth in claim 1 wherein controller is capable of determining the geographic location periodically.
5. The apparatus as set forth in claim 1 wherein controller is capable of determining the geographic location aperiodically.
6. The apparatus as set forth in claim 1 wherein said controller is capable of determining the geographic location in response to a discrete event.
7. The apparatus as set forth in claim 1 wherein said controller is capable of determining said geographic location from the server.
8. The apparatus as set forth in claim 1 wherein said memory further comprises a server access application program and an encryptiondecryption application program.
9. For use in a network server, an apparatus for transferring mobile station geographic location information associated with said mobile station to an authorized client access device, said apparatus comprising:
memory that comprises mobile station current position information and at least one encryptiondecryption key; and
a data processor, coupled to the memory, that is capable of storing the geographic location information in the memory, the data processor additionally capable of establishing a secure connection with the mobile station, using the at least one encryptiondecryption key, over the wireless network over which the geographic location information is transmitted.
10. The apparatus as set forth in claim 9 wherein said data processor is capable of determining said geographic location information using a geographic location determination technique.
11. The apparatus as set forth in claim 9 wherein said memory further comprises a mobile station record having a mobile station profile, an authorized client profile, and an encryptiondecryption key.
12. The apparatus as set forth in claim 11 wherein the mobile station profile comprises the geographic location information.
13. The apparatus as set forth in claim 9 wherein the controller is further capable of transmitting the geographic location information to the authorized client device in response to an authorized request from the authorized client device.
14. The apparatus as set forth in claim 13 wherein the authorized request comprises a password.
15. For use in a network server that is capable of communicating with a mobile station via a wireless network, a method of distributing mobile station geographic location information, the method comprising the steps of:
determining the mobile station geographic location information;
storing the mobile station geographic location information in a database in memory;
receiving an access request from a client access device for the geographic location information;
authenticating the access request for the geographic location information; and
transmitting the geographic location information to the client access device in response to an authentic access request.
16. The method as set forth in claim 15 wherein the step of determining the geographic location information comprises receiving the geographic location information in an encrypted form from the mobile station over a secure connection.
17. The method as set forth in claim 15 wherein the step of determining the geographic location information comprises the steps of:
determining the geographic location information using a triangulation technique;
storing the geographic location information in memory; and
transmitting the geographic location information to the mobile station.
18. The method as set forth in claim 15 wherein the step of transmitting comprises transmitting encrypted geographic location information to the client access device.
19. The method as set forth in claim 15 wherein the step of authenticating comprises determining if a password from the client access device is authentic.
20. The method as set forth in claim 15 wherein the step of authenticating comprises determining if a decryption key from the client access device is authentic.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An intervertebral implant consisting:
a first face for engaging a first vertebral endplate and a second face for engaging a second vertebral endplate, outer and inner walls extending between the faces, a central axis, an opening defined by the inner wall, a through-slot extending from the first face through to the second face and from the outer wall through to the inner wall, the through-slot aligned with the central axis;
wherein at least 95 percent by volume of the implant is formed of a radiolucent material with a modulus of elasticity between 1 GPa and 20 GPa;
wherein the first face and the second face each have a plurality of three-dimensional projections extending therefrom;
wherein at least one of the first and second faces is provided with at least one guide notch and the second face contains a perforation, the perforation not aligned with the central axis; and
wherein at least a portion of the implant is formed of a metallic, radiopaque material.
2. The intervertebral implant of claim 1 wherein the modulus of elasticity of the radiolucent material is between 3 GPa and 5 GPa.
3. The intervertebral implant of claim 1, wherein the implant further comprises at least one marker formed of a radiopaque material.
4. The intervertebral implant of claim 3, wherein at least one marker is no greater than 5 percent by volume of said intervertebral implant.
5. The intervertebral implant of claim 1, wherein a portion of the three-dimensional projections forms a grooved surface.
6. The intervertebral implant of claim 1, wherein at least a portion of the three-dimensional projections comprises teeth.
7. The intervertebral implant of claim 6, wherein the teeth are arranged in a regular pattern.
8. The intervertebral implant of claim 1, wherein at least a portion of the three-dimensional projections comprises a generally arcuate arrangement of teeth.
9. The intervertebral implant of claim 1, wherein the first and second faces are disposed transverse to each so that the cylinder has a wedge-shaped, tapered form.
10. The intervertebral implant of claim 9, wherein the first and second faces are disposed at an angle of between 10\xb0 and 20\xb0 with respect to each other.
11. The intervertebral implant of claim 1, wherein the radiolucent material is polyaryletherketone.
12. The intervertebral implant of claim 1, wherein at least one guide notch is disposed at an angle of between 30\xb0 and 60\xb0 with respect to the central axis.
13. The intervertebral implant of claim 1, wherein the ratio of the area of the first face and the free cross-sectional area of the opening defined by the inner wall is between 0.5 and 1.6.
14. The intervertebral implant of claim 1, wherein the outer wall is provided with at least one recess aligned with the central axis and extending between the first and second faces.
15. The intervertebral implant of claim 14, wherein the implant has a generally U-shaped form.
16. The intervertebral implant of claim 14, wherein the recess is aligned with the through-slot.
17. The intervertebral implant of claim 1, wherein the through-slot has a through-slot height defined between the first and second faces and the implant has a maximum height defined between the first and second faces, wherein the through-slot height is about the same as the maximum height of the implant.
18. The intervertebral implant of claim 1, wherein the outer wall comprises at least one retaining notch intersecting the through-slot.
19. The intervertebral implant of claim 1, wherein the outer wall comprises at least one retaining notch extending in a plane perpendicular to the central axis.
20. The intervertebral implant of claim 19, wherein the retaining notch is disposed equidistant from the first and second faces.
21. The intervertebral implant of claim 1, wherein the outer wall is provided with at least one perforation.
22. The intervertebral implant of claim 21, wherein at least one perforation has a shape selected from the group consisting of circular bores, slots, or elongate holes.
23. The intervertebral implant of claim 22, wherein at least one of the at least one perforation intersects a recess in the outer wall that is aligned with the central axis and extends between the first and second faces.
24. The intervertebral implant of claim 1, wherein the implant has a height between 12 and 23 mm.
25. The intervertebral implant of claim 1, wherein the implant has a height between 4.5 mm and 12.5 mm.
26. The intervertebral implant of claim 1, wherein the outer wall is disposed at a maximum distance of between 14 mm and 18 mm from the central axis.
27. The intervertebral implant of claim 1, wherein the outer wall is disposed at a maximum distance of between 5.5 mm and 9.5 mm from the central axis.
28. The intervertebral implant of claim 1, wherein the radiolucent material is selected from the group consisting of polyetheretherketones, ultra-high molecular weight polyethylenes, and polysulfones.

1. A continuous casting method, comprising the following steps of:
guiding molten steel from an immersion nozzle into a mold;
guiding a slab formed in said mold to a plurality of guide roll pairs;
bulging said slab by providing an increased spacing between a select number of the guide roll pairs to produce a bulged slab with a liquid core;
completing the solidification of a liquid core in a thickness-wise center part of said bulged slab at the position where the bulged slab is reduced, and
reducing the thickness of said bulged slab to a predetermined thickness with a reduction roll pair comprising an upper reduction roll and a lower reduction roll, wherein the uppermost surface of said lower reduction roll is projected a distance higher than a lower pass line for the slab, wherein the projection distance of the uppermost surface of the lower reduction roll from the lower pass line for the slab is based on a bulging thickness of the slab and the projection distance is the same as or not more than a bulging thickness of the bulged slab,
wherein by reducing the bulged slab, a Mn segregation index CC0 in the thickness-wise center part satisfies the relation expressed by the following equation (a) over the width W which is expressed by the following equation (b):
0.7\u2266CC0\u22661.2 \u2003\u2003(a), and
W=W0\u22122\xd7d\u2003\u2003(b)
where C: the Mn content (mass %) at the center part in the thickness direction of the slab,
C0: the mean Mn content (mass %) in the slab,
W0: the width of the slab (mm), and
d: the thickness of the solidified shell (the distance between an area of the slab with a solid fraction of 0.8 and a surface layer on a narrow side at the position of thickness reduction) (mm).

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for treatment of cancer comprising administering to a subject in need thereof a therapeutically effective dose of glufosfamide in combination with carboplatin and etoposide.
2. The method of claim 1 further comprising administering rituximab.
3. The method of claim 1 wherein said cancer is a lymphoma.
4. The method of claim 3 wherein said cancer is a non-Hodgkin’s lymphoma.
5. The method of claim 3 wherein said cancer is a Hodgkin’s lymphoma
6. The method of claim 1 wherein said glufosfamide is administered in the absence of mesna.
7. The method of claim 1 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
8. The method of claim 2 wherein said cancer is a lymphoma.
9. The method of claim 8 wherein said cancer is a non-Hodgkin’s lymphoma.
10. The method of claim 8 wherein said cancer is a Hodgkin’s lymphoma
11. The method of claim 2 wherein said glufosfamide is administered in the absence of mesna.
12. The method of claim 8 wherein said glufosfamide is administered in the absence of mesna.
13. The method of claim 2 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
14. The method of claim 3 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
15. The method of claim 4 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
16. The method of claim 5 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
17. The method of claim 6 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
18. The method of claim 8 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
19. The method of claim 9 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
20. The method of claim 10 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.